Feasibility Assessment of Cerebrospinal Fluid from HIV-1-Infected Children for HIV Proviral DNA and Monocyte Chemoattractant Protein 1 Alleles

2006 ◽  
Vol 54 (8) ◽  
pp. 468-472 ◽  
Author(s):  
Bruce Shiramizu ◽  
Emily Lau ◽  
Alyson Tamamoto ◽  
Justin Uniatowski ◽  
David Troelstrup
Keyword(s):  
Cerebrospinal Fluid ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Proviral Dna ◽  
Feasibility Assessment ◽  
Monocyte Chemoattractant Protein ◽  
Hiv 1 ◽  
Hiv Proviral Dna

scholarly journals The Human Immunodeficiency Virus Type 1 Tat Protein Up-Regulates the Promoter Activity of the Beta-Chemokine Monocyte Chemoattractant Protein 1 in the Human Astrocytoma Cell Line U-87 MG: Role of SP-1, AP-1, and NF-κB Consensus Sites

2000 ◽  
Vol 74 (4) ◽  
pp. 1632-1640 ◽  
Author(s):  
Siew Pheng Lim ◽  
Alfredo Garzino-Demo
Keyword(s):  
Human Immunodeficiency Virus ◽  
Promoter Activity ◽  
Tat Protein ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Monocyte Chemoattractant Protein ◽  
Astrocytoma Cell ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT It has been shown that the human immunodeficiency virus type 1 (HIV-1) Tat protein can specifically enhance expression and release of monocyte chemoattractant protein 1 (MCP-1) from human astrocytes. In this study, we show evidence that Tat-induced MCP-1 expression is mediated at the transcriptional level. Transient transfection of an expression construct encoding the full-length Tat into the human glioblastoma-astrocytoma cell line U-87 MG enhances reporter gene activity from cotransfected deletion constructs of the MCP-1 promoter. HIV-1 Tat exerts its effect through a minimal construct containing 213 nucleotides upstream of the translational start site. Site-directed mutagenesis studies indicate that an SP1 site (located between nucleotides −123 and −115) is critical for both constitutive and Tat-enhanced expression of the human MCP-1 promoter, as mutation of this SP1 site significantly diminished reporter gene expression in both instances. Gel retardation experiments further demonstrate that Tat strongly enhances the binding of SP1 protein to its DNA element on the MCP-1 promoter. Moreover, we also observe an increase in the binding activities of transcriptional factors AP1 and NF-κB to the MCP-1 promoter following Tat treatment. Mutagenesis studies show that an upstream AP1 site and an adjacent NF-κB site (located at −128 to −122 and −150 to −137, respectively) play a role in Tat-mediated transactivation. In contrast, a further upstream AP1 site (−156 to −150) does not appear to be crucial for promoter activity. We postulate that a Tat-mediated increase in SP1 binding activities augments the binding of AP1 and NF-κB, leading to synergistic activation of the MCP-1 promoter.

HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes

Blood ◽  
2001 ◽  
Vol 97 (2) ◽  
pp. 352-358 ◽  
Author(s):  
In-Woo Park ◽  
Jian-Feng Wang ◽  
Jerome E. Groopman
Keyword(s):  
Protein Kinase ◽  
Map Kinase ◽  
Dependent Manner ◽  
Endothelial Monolayer ◽  
Monocyte Chemoattractant Protein 1 ◽  
Pkc Inhibitor ◽  
Monocyte Chemoattractant ◽  
Monocyte Chemoattractant Protein ◽  
Infected Cells ◽  
Hiv 1

Abstract The mechanism whereby HIV-infected cells transit from the bloodstream into tissues is not well defined. This phenomenon was addressed by studying the effects of HIV-1 Tat, a protein secreted by infected cells, on human lung microvascular endothelial cells (HMVEC-Ls). It was found that monocyte chemoattractant protein-1 (MCP-1) was released from HMVEC-Ls in a dose- and time-dependent manner after Tat treatment. MCP-1 is a potent β-chemokine that recruits monocytes and T cells and promotes cell adhesion and transmigration across an endothelial monolayer. It was also observed that MCP-1 and the culture medium from Tat-treated HMVEC-Ls were chemotactic for CD14+ monocytes from human peripheral blood and for THP-1, a promonocytic cell line used as a model system. To characterize the signaling pathways underlying the observed induction of MCP-1, HMVEC-Ls were treated with 2 different protein kinase inhibitors: PD98059, a MAP kinase inhibitor, and GF109203X, a protein kinase C (PKC) inhibitor. MCP-1 release was significantly reduced when PKC was inhibited, and slightly decreased when PI3 kinase was blocked; no effect on MCP-1 release was observed on MAP kinase inhibition. Similarly, transmigration of THP-1 cells was significantly impaired by the PKC inhibitor, but not by the other tested inhibitors. These data indicate that the HIV-1 Tat protein may act as a protocytokine by causing the release of MCP-1 from the endothelial monolayer, and thereby facilitating monocyte transmigration into tissues via a PKC signaling pathway.

Sign in / Sign up

Export Citation Format

Share Document